Skip to main content

Table 4 Summary of efficacy data from observational studies and meta-analyses

From: A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

Outcome, months Lenvatinib Sorafenib
Range from observational studies Range from observational studies Estimate from meta-analysis by Thomas et al. 2014 [45] Estimate from meta-analysis by Shen et al. 2014 [44]
OS, median 31.8–32.3 [2] 23–34.5 [3] a - c - c
PFS, median 12.6–25.8 [2] 12–22.1 [4] b 17.9 - c
95% CI    17.9–18 [7]  
ORR, % 50–68 [2] 15–38.3 [7] 20.9 22
95% CI    14.3–27.5 [6] 15–28 [7]
  1. - = not applicable, CI Confidence interval, ORR Objective tumour response rate, OS Overall survival, PFS Progression-free survival
  2. aAn additional study reported that the median OS had not been met [28]
  3. bOne other study reported that the median PFS had not been met [28] and another reported mean PFS only (9.7 months) [30]; in this latter study sorafenib was studied at half the dose of all other studies and included only 9 patients
  4. c No meta-analyses were identified
  5. [x] denotes the number of studies from which data are derived